Drug Profile
PTI 501
Alternative Names: morphine-naloxoneLatest Information Update: 01 Apr 2019
Price :
$50
*
At a glance
- Originator Albert Einstein College of Medicine
- Developer Pain Therapeutics
- Class
- Mechanism of Action Opioid mu receptor agonists; Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 27 Mar 2019 Pain Therapeutics is now called Cassava Sciences
- 07 May 2002 Enrolment has been completed in a phase II clinical trial in patients with severe postoperative pain
- 11 Oct 2000 Phase-II clinical trials for Pain in USA (Injection)